CTI BioPharma Corp. (CTIC) reported its Q3 2020 financial results, showing an operating loss of $11 million and no revenues for the quarter. This is compared to an operating loss of $9.7 million and revenues of $2.3 million in Q3 2019. The company announced the initiation of a rolling New Drug Application (NDA) for pacritinib targeting myelofibrosis patients with severe thrombocytopenia, expecting to complete the NDA submission in Q1 2021. Cash and equivalents stood at $57.4 million, enough to fund operations into Q4 2021.
CTI BioPharma Corp. (Nasdaq: CTIC) announced an oral presentation highlighting the development of pacritinib for graft versus host disease (GVHD) at the 62nd American Society of Hematology Annual Meeting, scheduled for December 5-8, 2020. The abstract titled Biological and Clinical Impact of JAK2/mTOR Blockade in GVHD Prevention will be presented by Dr. Joseph Pidala during a session on December 6, 2020, at 10:00 a.m. PT. This presentation underscores CTIC's focus on innovative therapies targeting unmet medical needs in blood-related cancers.
CTI BioPharma Corp. (NASDAQ: CTIC) will announce its third quarter 2020 financial results on November 10, 2020, after the markets close. A conference call and webcast will follow at 4:30 p.m. ET to discuss results and provide a corporate update. The call can be accessed by phone at (877) 735-2860 (domestic) or (602) 563-8791 (international) with conference ID 5504037. A replay will be available for 30 days. CTI focuses on developing therapies for blood-related cancers, particularly myelofibrosis and COVID-19 treatment.
CTI BioPharma Corp. (Nasdaq: CTIC) has initiated a rolling New Drug Application (NDA) submission to the FDA for pacritinib, aimed at treating myelofibrosis patients with severe thrombocytopenia (platelet counts 50 x 10
CTI BioPharma Corp. (Nasdaq: CTIC) announced its plan to submit a New Drug Application (NDA) for pacritinib targeting myelofibrosis patients suffering from severe thrombocytopenia. Following a Pre-NDA meeting with the FDA, the NDA submission is set to begin in the coming weeks, aiming for completion in Q1 2021. This application will utilize data from completed Phase 3 trials (PERSIST-1, PERSIST-2) and the Phase 2 PAC203 trial. Currently, there are no approved treatments specifically for this patient group, indicating a significant unmet medical need.
CTI BioPharma Corp. (Nasdaq: CTIC) reported its financial results for Q2 2020, revealing an operating loss of $10.0 million, slightly improved from $11.0 million in Q2 2019. For the six months ended June 30, 2020, the operating loss was $21.9 million, up from $21.5 million in 2019. The company faced no revenue during this period, contrasting with $0.4 million and $1.1 million in the same periods of 2019. A net loss of $14.0 million was recorded for Q2 2020, equal to $(0.19) per share. Cash reserves remain robust at $70.1 million, forecasted to sustain operations through Q4 2021.